Form 13-F position report

MATINAS BIOPHARMA HLDGS INC CO

Reported by MORGAN STANLEY

MTNB CUSIP 576810105 Manager CIK 0000895421

Reported 39,869 shares, down 11,986 (23.1%) from the prior quarter.

Reported value -26.2%; share count -23.1% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2022
Shares 39,869 Quarter-end amount reported
Reported value $31,000 Fair value at quarter end
Consecutive quarters held 11 Through Q2 2022

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 71000
2022-03-31 42000
2022-06-30 31000
2022-09-30 13000
2022-12-31 19485
2023-03-31 17502
2023-06-30 10800
2023-09-30 3900
2023-12-31 5946
2024-03-31 12874
2024-06-30 7282
2024-09-30 1841
2024-09-30 0
2024-12-31 73
2025-03-31 75
2025-06-30 128
2025-09-30 1060
2025-12-31 328
2026-03-31 172
2026-06-30 211
2026-09-30 0
2026-09-30 20

Quarterly position history

How this manager's reported quarter-end position changed over time.

22 quarters
Quarterly reported position history for MATINAS BIOPHARMA HLDGS INC CO held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 New 8 +8 (0.0%) < 0.01% $20 2026-11-13
Q3 2026 Reduced 0 -344 (-100.0%) 0 $0 2026-11-13
Q2 2026 Unchanged 344 0 (0.0%) < 0.01% $211 2026-08-13
Q1 2026 Reduced 344 -217 (-38.7%) < 0.01% $172 2026-05-15
Q4 2025 Unchanged 561 0 (0.0%) < 0.01% $328 2026-02-13
Q3 2025 Added 561 +417 (289.6%) < 0.01% $1,060 2025-11-14
Q2 2025 Unchanged 144 0 (0.0%) < 0.01% $128 2025-08-15
Q1 2025 Unchanged 144 0 (0.0%) < 0.01% $75 2025-05-15
Q4 2024 Reduced 144 -376 (-72.3%) < 0.01% $73 2025-02-14
Q3 2024 Reduced 0 -46,000 (-100.0%) 0 $0 2024-11-14
Q3 2024 New 520 +520 (0.0%) < 0.01% $1,841 2024-11-14
Q2 2024 Reduced 46,000 -1,507 (-3.2%) < 0.01% $7,282 2024-08-14
Q1 2024 Added 47,507 +20,007 (72.8%) < 0.01% $12,874 2024-05-15
Q4 2023 Reduced 27,500 -2,501 (-8.3%) < 0.01% $5,946 2024-02-13
Q3 2023 Unchanged 30,001 0 (0.0%) < 0.01% $3,900 2023-11-15
Q2 2023 Reduced 30,001 -7,238 (-19.4%) < 0.01% $10,800 2023-08-14
Q1 2023 Reduced 37,239 -1,729 (-4.4%) < 0.01% $17,502 2023-05-15
Q4 2022 Added 38,968 +19,081 (95.9%) < 0.01% $19,485 2023-02-14
Q3 2022 Reduced 19,887 -19,982 (-50.1%) < 0.01% $13,000 2022-11-14
Q2 2022 Reduced 39,869 -11,986 (-23.1%) < 0.01% $31,000 2022-08-15
Q1 2022 Reduced 51,855 -18,500 (-26.3%) < 0.01% $42,000 2022-05-13
Q4 2021 Added 70,355 +15,896 (29.2%) < 0.01% $71,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

60 managers reported MATINAS BIOPHARMA HLDGS INC CO for Q2 2022.

Managers reporting MATINAS BIOPHARMA HLDGS INC CO in Q2 2022.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 8,414,074 +529,155 < 0.01% $6,647,000 21 qtrs
BlackRock Inc Added 4,343,639 +19,904 < 0.01% $3,431,000 21 qtrs
Sargent Investment Group LLC Added 3,960,900 +316,921 0.97% $3,129,000 11 qtrs
NEVILLE RODIE & SHAW INC Added 1,753,500 +1,736,000 0.12% $1,385,000 17 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 1,551,186 -79,491 < 0.01% $1,225,000 21 qtrs
Arkadios Wealth Advisors Unchanged 1,399,000 0 0.16% $1,105,000 5 qtrs
JTC Employer Solutions Trustee Ltd Unchanged 775,000 0 0.08% $630,000 5 qtrs
BRIDGEWAY CAPITAL MANAGEMENT LLC Unchanged 753,391 0 0.01% $595,000 14 qtrs
STATE STREET CORPORATION Unchanged 712,471 0 < 0.01% $563,000 11 qtrs
STALEY CAPITAL ADVISERS INC Unchanged 600,000 0 0.03% $474,000 13 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2022
Filed
August 15, 2022
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
8
Shared
0
None
39,861

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.